INMB News & Events

INmune Bio announces new preclinical data for INB03. The data will be presented at the American Association for Cancer Research, AACR, Annual Meeting 2026 in San Diego on April 17-22. Key Scientific Findings: Overcoming Resistance in Vitro: The combination of INB03 with either lapatinib or tucatinib produced statistically superior inhibition of cell proliferation and migration in both HER2+ JIMT-1 and brain-metastatic JIMT-1 Br3-luc cell lines compared to TKIs alone. Enhanced Tumor Control In Vivo: In female nude mice bearing JIMT-1 or JIMT-1 Br3-luc tumors, INB03 + TKI combinations markedly slowed tumor growth compared to TKIs alone. Reduction of Metastatic Spread: The addition of INB03 significantly reduced the incidence of metastases to brain, lung, and liver. Notably, it further enhanced tucatinib's effect on lung metastases. Mechanism of Action: These results support prior research showing that selective sTNF neutralization with INB03 down-regulates MUC4, a protein that shields the HER2 molecule and prevents therapies from binding effectively.

INmune Bio announced that it received the official minutes from its End-of-Phase 2 meeting with the U.S. Food and Drug Administration, FDA. The minutes confirm regulatory alignment on the Company's proposed integrated Phase 2b/3 clinical development strategy for XPro1595 in early Alzheimer's Disease. "The outcome of the End-of-Phase 2 interaction is an important inflection point for XPro1595," said CJ Barnum, PhD, Vice President of Neuroscience at INmune Bio. "The FDA's feedback on our enrichment-led design, primary endpoint, and integrated Phase 2b/3 structure validates our scientific and clinical strategy and provides a clearly defined regulatory path to advancing XPro1595 into a registration-intent program in early Alzheimer's disease."